Sodium Hydroxide → (3R,11aS)-1,2,3,11a-Tetrahydro-3,8-dihydroxy-7-methoxy-5H-pyrrolo(2,1-c)(1,4)benzodiazepin-5-one

HRID 2071882ノート

反応式

HRID 2071882 の反応式
[OH-].[Na+].[CH3:3][O:4][C:5]1[CH:10]=[C:9]2[C:11]([N:13]3[CH:17]([OH:18])[CH2:16][CH2:15][CH:14]3[CH:19]=[N:20][C:8]2=[CH:7][C:6]=1[OH:21])=[O:12]>>[CH3:3][O:4][C:5]1[CH:10]=[C:9]2[C:11](=[O:12])[N:13]3[C@@H:14]([CH2:15][CH2:16][C@@H:17]3[OH:18])[CH:19]=[N:20][C:8]2=[CH:7][C:6]=1[OH:21].[CH3:3][O:4][C:5]1[CH:10]=[C:9]2[C:11]([N:13]3[C@H:17]([OH:18])[CH2:16][CH2:15][C@H:14]3[CH:19]=[N:20][C:8]2=[CH:7][C:6]=1[OH:21])=[O:12]

参加物

4

実験手順

Crystalline methylneothramycin A (225 mg.) obtained in Example 8 was dissolved in 45 ml. of 0.01 NCHl-dioxane (1:1 in volume) and the solution was kept at room temperature (22° C.) for 1 hour. The solution was adjusted to pH 6.0 with 1 N NaOH and concentrated to dryness under reduced pressure, affording 216 mg. of a colorless powder containing neothramycins A and B. The powder was chromatographed on a column of silica gel (20 g.) by the similar manner as employed in Example 2. Pure neothramycin A (87 mg.) and neothramycin B (69 mg) were obtained.

後処理

  1. customCrystalline methylneothramycin A (225 mg.) obtained in Example 8
  2. dissolutionwas dissolved in 45 ml
  3. customwas kept at room temperature
  4. custom(22° C.)
  5. customfor 1 hour
  6. concentrationconcentrated to dryness under reduced pressure
  7. customaffording 216 mg
  8. customThe powder was chromatographed on a column of silica gel (20 g.) by the similar manner

出典と根拠

ORDレコード
ord-f62f7c1fa5f14a5d8d7f3625a782d228
出典データセット
uspto-grants-1977_09
特許番号
US04049497

反応ノート

読み込み中…